Smilebiotek Zhuhai

Smilebiotek Zhuhai Limited is a clinical-stage biotechnology company and a subsidiary of MingMed Biotech, dedicated to the discovery and development of first-in-class ophthalmology products. The company's pipeline focuses on therapies for dry age-related macular degeneration (AMD) and geographic atrophy. Its lead candidates include QA102, a first-in-class oral small molecule bacterial growth inhibitor that has completed Phase II trials, and QA108, a traditional Chinese medicine (TCM) formulation currently in Phase III clinical development. Smilebiotek utilizes a dual-track approach combining Western medicine and traditional Chinese medicine to address significant unmet medical needs in retinal diseases.